



**HAL**  
open science

## Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent

Olivier Vollmer, Charles-Ambroise Tacquard, Yannick Dieudonné, Benoit Nespola, Laurent Sattler, Lélia Grunebaum, Vincent Gies, Mirjana Radosavljevic, Charlotte Kaeuffer, Yves Hansmann, et al.

### ► To cite this version:

Olivier Vollmer, Charles-Ambroise Tacquard, Yannick Dieudonné, Benoit Nespola, Laurent Sattler, et al.. Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent. *Autoimmunity Reviews*, 2021, 20 (6), pp.102822. 10.1016/j.autrev.2021.102822. hal-03265100

**HAL Id: hal-03265100**

**<https://hal.science/hal-03265100>**

Submitted on 25 Apr 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## **Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent**

*Dear Editor,*

In the context of the COVID-19 pandemic, frequent thrombosis were reported, with up to 43% of clinically relevant thrombotic events in critically patients [1]. Several abnormalities in coagulation parameters, endothelial cells activation and multiple cytokines production have been described resulting in a procoagulant state [2]. A prolonged activated partial-thromboplastin time (aPTT) was identified in a significant number of patients, associated with the presence of a Lupus Anticoagulant (LA) [3–5]. Besides, studies showed an increased prevalence of other antiphospholipid antibodies (aPLs) with different targets and/or isotypes in infected patients [6,7]. aPLs appeared associated with thrombosis and severity of COVID-19 [6,8,9] and were demonstrated as pathogenic in a murine model with induced vascular injury [7]. Recent findings raise the question of whether LA and other aPLs persist over time and thereby whether COVID-19 with thrombosis and aPLs could be considered as an unusual, induced antiphospholipid syndrome (APS). Several concerns arise from the current literature on COVID-19. LA positivity could be difficult to interpret as many patients did not have LA detection with aPTT and diluted Russell's Viper Venom Time (dRVVT) at admission in the hospital. Moreover, the inflammatory context, coagulation disorders or anticoagulant therapy could influence LA detection [3,10]. Siguret et al. showed LA as labile when measured a few days after first identification [11] but there is to date no systematic follow-up of the patients who presented COVID-19 infection and LA and/or aPLs. In the present study we aimed to describe the prevalence and persistence over time of criteria aPLs in a cohort of hospitalized COVID-19 patients who were tested positive for LA and assess their association with thrombosis.

Included patients were at least 18 years of age, had RT-PCR confirmed SARS-CoV-2 severe to critical infection according to WHO guidelines [12] and were positive for LA, between March 03<sup>rd</sup> and April 11<sup>th</sup> 2020. Study was approved by the Institutional Board of Strasbourg University Hospital (CE-2020-85). Data were collected from routine care. LA activity of patient plasma was assessed by the dRVVT (STA®-Staclot dRVV Screen and confirm reagent, Stago), and LA sensitive aPPT (STA®-PPT LA reagent, Stago) according to ISTH guidelines [13]. IgM and IgG anticardiolipin antibodies (aCLs) were evaluated through a fluorescence enzyme immunoassay (FEIA) designed as a sandwich assay on a

Phadia 250 (ThermoFisher, Phadia Uppsala Sweden). Anti- $\beta$ 2GPI antibodies were assessed using a sandwich ELISA (Inova Diagnostic, San Diego, CA, USA). Non-criteria aPLs titers were determined by ELISA. Screening for antinuclear antibodies (ANAs) was performed on HEp-2 cells (Zeus Scientific, USA). Fisher's exact test was used for categorical variables and Mann Whitney or unpaired t-test were used for quantitative variables according to variable distribution. Multivariate analysis including variable with  $P$  value  $< 0.10$  on univariate analysis was performed using multiple logistic regression. Statistical analysis was performed with JMP software version 7.10 (SAS institute, USA).

We identified 79 patients with COVID-19 and LA (Figure 1). Patients characteristics were concordant with previously published data [14,15]. Patients had severe to critical COVID-19 with hospitalization for a median duration of 23 days [5-59] and 66 (83.5%) required mechanical ventilation (Table 1). Computed tomography (CT) quantification of pneumonia was performed for 69 patients with at least 25% involvement in the majority of cases (85.5%). All patients received standard of care as needed. Among the 79 LA positive patients, 50.6% displayed one thrombosis with 7.59% having at least one recurrence. Regarding the vascular distribution of thrombosis, 75% had venous thrombosis, 25% had arterial thrombosis and 25% had a catheter or ECMO oxygenator or Renal Replacement Therapy circuit clotting. Importantly, 82.5% of patients with thrombosis received a prophylaxis either with low molecular weight heparin (LMWH) or unfractionated heparin (UFH) before the first thrombotic event. The median highest CRP was 286 mg/l [16.7-492] and the median highest D-Dimer level was 7200  $\mu$ g/l [730-20000].

Fifty-six patients with LA were further explored for other criteria aPLs with 14 being positive according to laboratory values (table 1). Three had anti- $\beta$ 2GPI IgM, 13 had aCL IgM and 1 had aCL IgG. Fifty-three patients were explored for non-criteria aPLs and 20 were positive for at least one non criteria aPL among anti-Phosphatidylserine (PS), anti-Phosphatidyl-ethanolamine (PE), anti-prothrombin (PT), anti-annexin V (AV). Altogether, 29 were positive for criteria or non-criteria aPLs. Additionally, 53 patients with LA were explored for antinuclear antibodies (ANAs). Noteworthy, 33 (62.3%) tested patients were positive for ANAs at a titer  $>1/80$  and 15 (24.5%) above 1/320 dilution.

We compared the patients with thrombosis and without thrombosis among the 79 patients with LA (Table 1). Groups were similar for age, sex and BMI, cardiovascular risk factors and previous history of thrombotic events. There was no difference regarding COVID severity and anticoagulant therapies. We

found a strong association between thrombosis and positivity of aCLs IgM (11/27 [41%] patients with thrombosis vs 2/29 [7%] patients without thrombosis,  $p = 0.004$ , OR=9.28 IC95 2.0 to 44.4).

Forty-two patients were followed-up and screened for antiphospholipid antibodies and ANAs at least 3 months and up to 6 months after first LA identification (Table 1). LA was found negative in all of 42 patients. The presence of aCLs was noted in 7/42 (16.7%) patients, mostly IgM aCLs. Anti- $\beta$ 2-GPI were found in 1/42 (2.38%) patients. Non-criteria aPLs were found in 5/42 (11.9%) patients, mostly anti-prothrombin. Overall, 10/42 (23.8%) patients had at least one positive aPL. The association between thrombosis and positivity of aCLs IgM was confirmed (5/20 [25%] patients with thrombosis vs 0/22 patients without thrombosis). Of note, 22/42 (52.4%) patients still remained positive for ANAs with a titer above 1/80 and 11 of 42 (26.2%) above 1/320 dilution. None of the 42 patients had a new episode of thrombosis during follow-up and none of them presented autoimmune manifestations.

In conclusion, LA is frequent in COVID-19 patients in the acute phase, but its signification is controversial. Herein we show that LA is transient. Based on our study and others, LA with aCLs of IgM or IgG isotype is strongly associated with the occurrence of thrombosis during the acute phase of COVID-19 infection [9]. In these situations, reinforced preventive anticoagulation is mandatory. Interestingly aCLs including of IgM isotype, can persist, in association with ANAs, suggesting that COVID-19 promotes a durable breakdown of tolerance and questioning the needed duration of follow-up in these patients. Viral infections are known to stimulate autoreactive B-cells and patients can transiently produce non-pathogenic aPLs, especially of IgM isotype, which are usually not associated with thrombosis. Thus, potentially thrombogenic aPLs in COVID-19 is an uncommon situation. COVID-19 infection is associated with coagulation disorders and a strong inflammatory context which could favor this breakdown of tolerance [16]. aPLs may be generated via molecular mimicry with some viral proteins [17,18]. Recent studies describe a SARS-CoV-2 induced vasculopathy and endothelial damage which could increase the pathogenicity of aPLs, or PLs and their cofactor exposition [19]. Therefore, considering the two-hit hypothesis, widely accepted as mechanism of thrombus formation in APS, COVID-19 may provide both first (aPLs emergence) and second hit (vascular damage) necessary for thrombosis [20]. Further experimental settings about the specificity and avidity of COVID-19 induced aPLs are likely required.

## Fundings

None.

## Disclosure of conflicts of interest

None.

## Acknowledgments

We thank the European reference Networks (ERNs) RITA and ReCONNET.

## Key words

COVID-19; SARS-CoV-2; APS, anti-phospholipid antibodies; lupus anticoagulant; thrombosis

## References

- [1] Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med* 2020;46:1089–98. <https://doi.org/10.1007/s00134-020-06062-x>.
- [2] Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood* 2020;135:2033–40. <https://doi.org/10.1182/blood.2020006000>.
- [3] Reyes Gil M, Barouqa M, Szymanski J, Gonzalez-Lugo JD, Rahman S, Billett HH. Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Netw Open* 2020;3:e2017539. <https://doi.org/10.1001/jamanetworkopen.2020.17539>.
- [4] Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. *N Engl J Med* 2020;383:288–90. <https://doi.org/10.1056/NEJMc2013656>.
- [5] Harzallah I, Debliquis A, Drénou B. Lupus anticoagulant is frequent in patients with Covid-19. *J Thromb Haemost JTH* 2020;18:2064–5. <https://doi.org/10.1111/jth.14867>.
- [6] Bertin D, Brodovitch A, Beziante A, Hug S, Bouamri A, Mege JL, et al. Anti-cardiolipin IgG autoantibodies are an independent risk factor of COVID-19 severity. *Arthritis Rheumatol Hoboken NJ* 2020. <https://doi.org/10.1002/art.41409>.
- [7] Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. *Sci Transl Med* 2020. <https://doi.org/10.1126/scitranslmed.abd3876>.
- [8] Pineton de Chambrun M, Frere C, Miyara M, Amoura Z, Martin-Toutain I, Mathian A, et al. High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability? *J Intern Med* 2020. <https://doi.org/10.1111/joim.13126>.
- [9] Le Joncour A, Frere C, Martin-Toutain I, Gougis P, Ghillani-Dalbin P, Maalouf G, et al. Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. *Autoimmun Rev* 2020:102729. <https://doi.org/10.1016/j.autrev.2020.102729>.
- [10] Platton S, Bowles L, Pasi KJ. Lupus Anticoagulant in Patients with Covid-19. Reply. *N Engl J Med* 2020;383:1893–4. <https://doi.org/10.1056/NEJMc2027508>.
- [11] Siguret V, Voicu S, Neuwirth M, Delrue M, Gayat E, Stépanian A, et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? *Thromb Res* 2020;195:74–6. <https://doi.org/10.1016/j.thromres.2020.07.016>.
- [12] Clinical management of COVID-19 n.d. <https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19> (accessed February 3, 2021).
- [13] Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost JTH* 2009;7:1737–40. <https://doi.org/10.1111/j.1538-7836.2009.03555.x>.

- [14] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet Lond Engl* 2020;395:497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- [15] Kaeuffer C, Le Hyaric C, Fabacher T, Mootien J, Dervieux B, Ruch Y, et al. Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull* 2020;25. <https://doi.org/10.2807/1560-7917.ES.2020.25.48.2000895>.
- [16] Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D, et al. Covid-19 and autoimmunity. *Autoimmun Rev* 2020;19:102597. <https://doi.org/10.1016/j.autrev.2020.102597>.
- [17] Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni P. Infectious origin of the antiphospholipid syndrome\*. *Ann Rheum Dis* 2006;65:2–6. <https://doi.org/10.1136/ard.2005.045443>.
- [18] Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. *Immunol Res* 2020:1–4. <https://doi.org/10.1007/s12026-020-09152-6>.
- [19] Magro CM, Mulvey J, Kubiak J, Mikhail S, Suster D, Crowson AN, et al. Severe COVID-19: A multifaceted viral vasculopathy syndrome. *Ann Diagn Pathol* 2021;50:151645. <https://doi.org/10.1016/j.anndiagpath.2020.151645>.
- [20] Noureldine MHA, Nour-Eldine W, Khamashta MA, Uthman I. Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome. *Semin Arthritis Rheum* 2019;48:860–6. <https://doi.org/10.1016/j.semarthrit.2018.08.004>.

Olivier Vollmer (Resident)<sup>1\*</sup>, Charles Tacquard (MD)<sup>2\*</sup>, Yannick Dieudonné (MD)<sup>1</sup>, Benoit Nespola (MD)<sup>3</sup>, Laurent Sattler (MD)<sup>4</sup>, Lélia Grunebaum (MD)<sup>4</sup>, Vincent Gies (PharmD, PhD)<sup>1</sup>, Mirjana Radosavljevic (MD, PhD)<sup>3</sup>, Charlotte Kaeuffer (MD)<sup>5</sup>, Yves Hansmann (MD)<sup>5</sup>, Jean-Christophe Weber (MD, PhD)<sup>6</sup>, Thierry Martin (MD, PhD)<sup>1</sup>, Laurent Arnaud (MD, PhD)<sup>7</sup>, Olivier Morel (MD, PhD)<sup>8</sup>, Aurélien Guffroy (MD, PhD)<sup>1</sup>, Olivier Collange (MD)<sup>2</sup>, Paul Michel Mertes (MD)<sup>2</sup>, Anne-Sophie Korganow (MD, PhD)<sup>1</sup>, Xavier Delabranche (MD, PhD)<sup>2\*\*</sup>, Vincent Poindron (MD, PhD)<sup>1\*\*</sup>

\* OV and CT participated equally to this work

\*\*XD and VP contributed equally to this work

## **Affiliations**

<sup>1</sup> Service d'Immunologie Clinique-Médecine Interne, Centre National de Référence des Maladies Auto-immunes et Systémiques Rares Est/Sud-Ouest RESO, Hôpitaux Universitaires de Strasbourg, France

<sup>2</sup> Service d'Anesthésie-Réanimation, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

<sup>3</sup> Laboratoire d'Immunobiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

<sup>4</sup> Laboratoire d'Hématologie, Unité d'Hémostase, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

<sup>5</sup> Service de Maladies Infectieuses et Tropicales-Médecine Interne, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France

<sup>6</sup> Service de Médecine Interne, Hôpitaux Universitaires de Strasbourg, France

<sup>7</sup> Service de Rhumatologie, Centre National de Référence des Maladies Auto-immunes et Systémiques Rares Est/Sud-Ouest RESO, Hôpitaux Universitaires de Strasbourg, France

<sup>8</sup> Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, France

## **Corresponding author :**

Dr Vincent Poindron, MD, PhD

Service d'Immunologie Clinique, Nouvel Hôpital Civil, 67091 Strasbourg, France

Phone: + 33 3 69 55 05 21; Fax: + 33 3 88 61 06 80

E-mail: [vincent.poindron@chru-strasbourg.fr](mailto:vincent.poindron@chru-strasbourg.fr)

**Table 1**

Characteristics and biological parameters of SARS-CoV-2 infected patients with LA and association with thrombotic events

|   | <b>Thrombosis<br/>N=40</b> | <b>No Thrombosis<br/>N=39</b> | <b>Univariate<br/>analysis<br/><i>p</i>*</b> | <b>Multivariate<br/>analysis<br/><i>p</i>**</b> |
|---|----------------------------|-------------------------------|--|---|
| Age <sup>1</sup>  | 65 [29-81]                 | 64 [24-86]                    | 0.51   |   |
| Sex ratio (F/M)   | 9/31                       | 7/32                          | 0.78   |   |
| BMI <sup>2</sup>  | 28 [21-41]                 | 29 [22-31]                    | 0.46   |   |
| <b>Co-existing conditions (n, %)</b>                              |                            |                               |  |   |
| HTA   | 19(48)                     | 16(41)                        | 0.65   |   |
| Diabetes  | 14(35)                     | 10(26)                        | 0.46   |   |
| Smoker  | 3(8)                       | 3(8)                          | 0.99   |   |
| Respiratory disease   | 4(10)                      | 6(15)                         | 0.85   |   |
| Cardiac arrhythmia  | 2(5)                       | 0                             | 0.49   |   |
| <b>Past medical history (n, %)</b>                                |                            |                               |  |   |
| Thrombotic events   | 1(3)                       | 2(5)                          | 0.61   |   |
| Malignancy  | 3(8)                       | 1(3)                          | 0.61   |   |
| <b>Therapy on arrival (n, %)</b>                                  |                            |                               |  |   |
| Long term LDA treatment   | 8(20)                      | 3(8)                          | 0.11   | 0.11  |
| Long term anticoagulant   | 1(3)                       | 0                             | 0.99   |   |
| Thromboprophylaxis  | 22(55)                     | 27(69)                        | 0.11   | 0.16  |
| LMWH  | 19(48)                     | 25(64)                        | 0.11   |   |
| UFH   | 3(8)                       | 2(5)                          | 0.99   |   |
| <b>Thrombotic events</b>  |                            |                               |  |   |
| Recurrence >1/>2  | 40(50.6)                   |                               |  |   |
| Delay between COVID-19 first symptoms and thrombosis <sup>3</sup> | 6/2                        |                               |  |   |
| Delay between inflammatory peak and thrombosis <sup>3</sup>       | 19 [4-38]                  |                               |  |   |
| Anticoagulation before first thrombosis                           | 6.5 [0-23]                 |                               |  |   |
| Venous thrombosis   | 33(82.5)                   |                               |  |   |
| Pulmonary thrombosis  | 30(75)                     |                               |  |   |
| Deep or superficial vein thrombosis                               | 27(67.5)                   |                               |  |   |
| Arterial thrombosis   | 5(12.5)                    |                               |  |   |
| Acute cerebral infarction   | 10(25)                     |                               |  |   |
| Mesenteric infarction   | 9(22.5)                    |                               |  |   |
| Myocardial infarction   | 1(2.5)                     |                               |  |   |
| Catheter thrombosis   | 0                          |                               |  |   |
| ECMO or RRT circuit Clotting                                      | 5(12.5)                    |                               |  |   |
| <b>Covid-19 therapy</b>   |                            |                               |  |   |
| Lopinavir-Ritonavir   | 24 (60)                    | 20 (51)                       | 0.43   |   |
| Hydroxychloroquine  | 7 (17.5)                   | 10 (25.5)                     | 0.38   |   |
| Remdesivir  | 2 (5)                      | 1 (2.5)                       | 0.57   |   |
| Interferon beta   | 2 (5)                      | 0                             | 0.16   |   |
| Anakinra  | 1 (2.5)                    | 0                             | 0.32   |   |
| Tocilizumab   | 1 (2.5)                    | 0                             | 0.32   |   |
| <b>Imaging features</b>   |                            |                               |  |   |
| Infiltrates <25% on CT  | 5/34(15)                   | 5/35(14)                      | 0.99   |   |
| Infiltrates >50% on CT  | 22/34(65)                  | 21/35(60)                     | 0.80   |   |
| <b>Outcome</b>  |                            |                               |  |   |
| ICU admission (n, %)  | 33(83)                     | 34(87)                        | 0.76   |   |
| Invasive mechanical ventilation                                   | 32(80)                     | 34(87)                        | 0.39   |   |
| Time to hospital discharge <sup>3</sup>                           | 25(8-59)                   | 22(5-49)                      | 0.31   |   |
| Death   | 4(10)                      | 3(8)                          |  |   |



| <b>Laboratory findings during hospitalization</b>   |              |               |               |             |
|---|--------------|---------------|---------------|-------------|
| Criteria aPLs (n/assessed, %)                       | 11/27(41)    | 3/29(10)      | <b>0.01</b>   |             |
| aCL IgM   | 11/27(41)    | 2/29(7)       | <b>0.004</b>  | <b>0.09</b> |
| aCL IgG   | 1/27         | 0             | 0.48          |             |
| Anti-β <sub>2</sub> GPI IgM                         | 2/27(7)      | 1/29(3)       | 0.60          |             |
| Anti-β <sub>2</sub> GPI IgG                         | 0            | 0             |               |             |
| Non-criteria aPLs                                   | 6/26(23)     | 7/27(26)      | 0.99          |             |
| PE  | 1/26(4)      | 0             | 0.61          |             |
| PS  | 0            | 1/27(4)       | 0.99          |             |
| PT  | 5/26 (19)    | 5/27(19)      | 0.99          |             |
| AV  | 0            | 1/27(4)       | 0.99          |             |
| ANAs  | 18/27(67)    | 16/26(61)     | 0.78          |             |
| High-sensitivity CRP at the peak (mg/l)             | 290 [16-437] | 285 [121-492] | 0.09          | 0.46        |
| <b>Laboratory findings at follow-up<sup>4</sup></b> |              | Thrombosis    | No Thrombosis |             |
|   |              | N=20          | N=22          |             |
| Criteria aPLs (n/assessed, %)                       | 7/20(35)     | 1/22(4.55)    |               |             |
| aCL IgM   | 5/20(25)     | 0             |               |             |
| aCL IgG   | 1/20(5)      | 1/22(4.55)    |               |             |
| Anti-β <sub>2</sub> GPI IgM                         | 0            | 0             |               |             |
| Anti-β <sub>2</sub> GPI IgG                         | 1/20(5)      | 0             |               |             |
| Non-criteria aPLs                                   | 5/20(25)     | 0             |               |             |
| PE  | 0            | 0             |               |             |
| PS  | 1/20(5)      | 0             |               |             |
| PT  | 5/20(25)     | 0             |               |             |
| AV  | 0            | 0             |               |             |
| ANAs  | 15/20        | 7/22          |               |             |

Note: results are given in median [Range], n(%) or n/N(%), where N is the total number of patients with available data. <sup>1</sup> Age is expressed in years; <sup>2</sup> BMI is expressed in kg/m<sup>2</sup>; <sup>3</sup> Delays between COVID-19 first symptoms/inflammatory peak and thrombosis and time to hospital discharge are expressed in days; <sup>4</sup> Patients were followed up 3 to 6 months after first LA identification. \* Difference using Fisher's exact test for categorical variables and Mann Whitney or unpaired t-test according to distribution for quantitative variables. \*\*Using multiple logistic regression. Abbreviations: BMI, Body Mass Index; LDA, Low Dose Aspirine; UFH, Unfractionated Heparin; LMWH, Low Molecular Weight Heparin; ECMO, Extra Corporeal Membrane Oxygenation; RRT, Renal Replacement Therapy; CT, Computed Tomography; ICU, Intensive Care Unit; aPLs, antiphospholipid antibodies (Ab); aCL, anticardiolipin Ab; PS, Anti-Phosphatidylserine Ab; PE, anti-Phosphatidyl-ethanolamine Ab; PT, anti-prothrombin Ab; AV, anti-annexin V Ab; ANAs, antinuclear Abs.

**Figure 1**  
Flowchart of the study

